^
    Back
    Association details:
    Biomarker:GNAQ mutation
    Cancer:Uveal Melanoma
    Drug:tris DBA palladium (Tris DBA) (NLRP3 inhibitor, ARF6 inhibitor, GNAQ inhibitor, NMT-1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    New
    Source:
    Oncotarget
    Title:

    Tris DBA palladium is an orally available inhibitor of GNAQ mutant uveal melanoma in vivo

    Excerpt:
    ...Tris DBA palladium was orally effective against GNAQ mutant melanoma in vivo.
    DOI:
    10.18632/oncotarget.27040